What is Graybug Vision, Inc. (GRAY)?

Graybug Vision, Inc. (GRAY) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of GRAY?

The current price of GRAY is $5.50. Prices are updated in real time on Stocks360.

What is GRAY's price-to-earnings (PE) ratio?

GRAY's trailing twelve-month PE ratio is -4.07, based on current price and earnings per share data available on Stocks360.

What is GRAY's market capitalization?

GRAY's market capitalization is $120,983,500.00, placing it in the small-cap tier.

Graybug Vision, Inc. (GRAY)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$5.50

Market Cap

$120.98M

PE (TTM)

-4.07

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.20

Day Range

$5.02 – $6.00

52-wk Range

$4.88 – $20.30

Avg Volume

N/A

Volume

24.63K

Graybug Vision, Inc. (GRAY) is a publicly traded company in the Healthcare sector. Latest price: $5.50. Market cap $120.98M. Trailing PE -4.07. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

May 8, 2023

EPS $-15.88 vs est. $-0.45

Missed by $15.43

Proprietary Signals

Signal snapshot temporarily unavailable.

About Graybug Vision, Inc.

Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema. Furthermore, GB-102 is being explored as a treatment for diabetic retinopathy. The company's pipeline also includes GB-401, an intraocular implant designed to deliver a beta-adrenergic receptor inhibitor, intended for the management of primary open-angle glaucoma. Initially established as Graybug LLC in 2011, the firm rebranded to Graybug Vision, Inc. in 2016 and is headquartered in Redwood City, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-4.07×
P/S (TTM)	0.00×
P/B	14975.92×
PEG	0.03×
P/FCF (TTM)	-6.33×
EV / EBITDA	-13.75×
EV / Sales	0.00×
Earnings Yield	-0.03%
Free Cash Flow Yield	-15.80%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$102.37M
Net Income (TTM)	-$31.12K
Free Cash Flow (TTM)	-$19.76M
Net Debt	-$18.62M
Working Capital	$15.97M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	3398.40%
Return on Invested Capital	-122.56%